The Society for Clinical Research Sites (SCRS) has announced the addition of a patient engagement and retention platform to its member benefit package. Offered in partnership with TrialScout, the platform will help SCRS member sites build their brand with patients and sponsors, providing access to patient experience ratings and reviews and monthly analytics to optimize site operations.
Available to qualifying member sites domestically and abroad as a part of the SCRS Member Affinity Program (MAP), member sites now have access to the following services:
“TrialScout’s patient experience platform is focused on empowering site success and recognizing site excellence,” said CEO Dr. Irfan Khan. “SCRS member sites are the very sites we feel are best suited to benefit from TrialScout’s ability to enhance the patient experience in clinical research.”
“Through TrialScout, SCRS member sites will be able to gain a deeper understanding into how they are perceived by their communities and patients, and will have access to a new means to showcase their capabilities with the sponsors and CROs they work with,” said SCRS VP of global engagement, Dan Milam. “We are thrilled to add TrialScout’s patient engagement and retention platform as our second MAP offering as an additional way to enhance site sustainability.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.